# An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension - A Long-Term Follow-Up to Protocol TDE-PH-310

Published: 10-08-2012 Last updated: 26-04-2024

To provide UT-15C for eligible subjects who participated in study protocol TDE-PH-310

**Ethical review** Approved WMO

**Status** Recruitment stopped

Health condition type Vascular hypertensive disorders

Study type Interventional

# **Summary**

#### ID

NL-OMON50371

#### Source

**ToetsingOnline** 

#### **Brief title**

Open-label study of UT-15C in PAH patients

#### **Condition**

Vascular hypertensive disorders

#### **Synonym**

increased pressure in pulmonary arteries, PAH

#### Research involving

Human

## **Sponsors and support**

**Primary sponsor:** United Therapeutics Corp

Source(s) of monetary or material Support: United Therapeutics

#### Intervention

**Keyword:** open-label, Pulmonary hypertension, UT-15C

#### **Outcome measures**

#### **Primary outcome**

The primary objective of this study is to provide UT-15C sustained release tablets for eligible subjects who participated in TDE-PH-310.

#### **Secondary outcome**

- To assess the long-term safety of oral UT-15C
- To assess the effect of continued long-term therapy with UT-15C on exercise capacity (six minute walk distance [6MWD] Borg dyspnea score), World Health Organization (WHO) Functional Class, and N- terminal pro-brain natriuretic peptide (NT proBNP) (at Week 48 only)

Exploratory Objective: Optional evaluation of pharmacogenomics

# **Study description**

#### **Background summary**

Pulmonary arterial hypertension (PAH), defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to heart failure and death.

The typical etiologies of PAH include idiopathic, heritable or associated with collagen vascular/connective tissue disease, portal hypertension, infection with the human immunodeficiency virus (HIV), a history of cocaine inhalation, or exposure to appetite suppressant drugs. An estimated annual incidence of approximately 2 cases per million has been reported for idiopathic PAH. [Rich, 1987; Rubin 1997]

There are three major factors thought to contribute to the increased pulmonary vascular resistance seen in this disease: vasoconstriction, remodeling of the vessel wall, and thrombosis. There are a number of metabolic pathways which contribute to these changes that involve vasoactive mediators such as the vasodilators nitric oxide and prostacyclin, and the vasoconstrictor endothelin-1. These substances affect both vascular tone and remodeling leading to their use as pharmacologic targets. [Farber, 2004]

Approved pharmacotherapies for PAH include: (1) intravenous prostacyclin (epoprostenol sodium or Flolan®); (2) the prostacyclin analogues, subcutaneous (SC), intravenous (IV), and inhaled treprostinil sodium (Remodulin®; Tyvaso®) and inhaled iloprost (Ventavis®); (3) the oral phosphodiesterase-5 inhibitors (PDE5-I), tadalafil (Adcirca®) and sildenafil (Revatio®); and (4) the oral endothelin receptor antagonists, bosentan (Tracleer®) and ambrisentan (Letairis®, Volibris®) [Barst, 2009].

#### Study objective

To provide UT-15C for eligible subjects who participated in study protocol TDE-PH-310

#### Study design

Multi-center, open-label study for eligible patients who participated in TDE-PH-310.

#### Intervention

/

#### Study burden and risks

/

## **Contacts**

#### **Public**

**United Therapeutics Corp** 

T.W. Alexander Drive 55 Research Triangle Park, NC 27709 US

#### **Scientific**

**United Therapeutics Corp** 

T.W. Alexander Drive 55 Research Triangle Park, NC 27709 US

## **Trial sites**

### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

#### **Inclusion criteria**

- 1. The subject voluntarily provides informed consent to participate in the study.
- 2. The subject participated in study TDE-PH-310 and met the definition of clinical worsening (as specified in Protocol TDE PH 310), remained on study drug, was compliant with study procedures and assessments during the TDE-PH-310 Study or was currently enrolled in that study at the time the study was discontinued by the sponsor.
- 3. All WOCBP must practice true abstinence from intercourse when it is in line with their preferred and usual lifestyle, or use 2 different forms of highly effective contraception for the duration of the study, and for at least 30 days after discontinuing study medication. Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptives (such as birth control pills), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, (3) an intrauterine device or (4) partner vasectomy. For women of childbearing potential, a negative urine pregnancy test is required at Baseline (study entry) prior to initiating study medication. WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea for at least 12 consecutive months].
- 4. Males participating in the study must use a condom during the length of the study, and for at least 48 hours after their last dose of study medication.

#### **Exclusion criteria**

- 1. The subject is pregnant or lactating.
- 2. The subject has received infused or inhaled prostacyclin therapy for 29 days or more.
- 3. The subject was prematurely discontinued from study TDE-PH-310 for reasons other than a clinical worsening event.
- 4. The subject developed a concurrent illness or condition during the conduct of TDE PH 310 which, in the opinion of the Investigator, would represent a risk to overall health if they enrolled in this study.

# Study design

## **Design**

Study phase: 3

Study type: Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 31-07-2014

Enrollment: 4

Type: Actual

## Medical products/devices used

Product type: Medicine

Brand name: /

Generic name: oral treprostinil diethanolamine

# **Ethics review**

Approved WMO

Date: 10-08-2012

Application type: First submission

Review commission: METC Amsterdam UMC

Approved WMO

Date: 08-02-2013

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 05-03-2013

Application type: First submission

Review commission: METC Amsterdam UMC

Approved WMO

Date: 29-07-2013

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 23-08-2013

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 17-06-2014

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 01-07-2014

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 07-04-2015

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 16-04-2015

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 15-06-2015

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 09-01-2017

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 19-01-2017

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 27-07-2017

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 03-10-2017

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 20-12-2018

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 02-04-2019

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 16-05-2019

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 03-07-2019

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 27-05-2020

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 17-06-2020

Application type: Amendment

Review commission: METC Amsterdam UMC

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

# Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

EudraCT EUCTR2012[000098[21-NL

ClinicalTrials.gov NCT01560637 CCMO NL41022.029.12